Enasidenib (Figure 1(a)) was a small molecule isocitrate dehydrogenase-2 (IDH2) inhibitor and was approved in the USA on 1 August 2017 for the treatment of patients with relapsed or refractory AML and IDH2 mutations [5, 6]. Here, IDH2 is linked to acute myeloid leukemia.